{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:08:27Z","timestamp":1761743307127},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2010,1,6]],"date-time":"2010-01-06T00:00:00Z","timestamp":1262736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2010,1,6]],"date-time":"2010-01-06T00:00:00Z","timestamp":1262736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1007\/s00280-009-1237-9","type":"journal-article","created":{"date-parts":[[2010,1,5]],"date-time":"2010-01-05T06:52:35Z","timestamp":1262674355000},"page":"811-815","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy"],"prefix":"10.1007","volume":"65","author":[{"given":"P.","family":"Mathew","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Tannir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. M.","family":"Tu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. M.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. B.","family":"Bekele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Pagliaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,1,6]]},"reference":[{"key":"1237_CR1","first-page":"1888","volume":"7","author":"WD Figg","year":"2001","unstructured":"Figg WD, Dahut W, Duray P, Hamilton M, Tompkins A et al (2001) A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res 7:1888\u20131893","journal-title":"Clin Cancer Res"},{"key":"1237_CR2","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1200\/JCO.2004.05.074","volume":"22","author":"WL Dahut","year":"2004","unstructured":"Dahut WL, Gulley JL, Arlen PM, Liu Y, Fedenko KM et al (2004) Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 22:2532\u20132539","journal-title":"J Clin Oncol"},{"key":"1237_CR3","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3816\/CGC.2006.n.031","volume":"5","author":"P Mathew","year":"2006","unstructured":"Mathew P, Logothetis CJ, Dieringer PY, Chen I, Pagliaro LC (2006) Thalidomide\/estramustine\/paclitaxel in metastatic androgen-independent prostate cancer. Clin Genitourin Cancer 5:144\u2013149","journal-title":"Clin Genitourin Cancer"},{"key":"1237_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1053\/j.seminoncol.2005.06.018","volume":"32","author":"R Knight","year":"2005","unstructured":"Knight R (2005) IMiDs: a novel class of immunomodulators. Semin Oncol 32:24\u201330","journal-title":"Semin Oncol"},{"key":"1237_CR5","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1200\/JCO.2004.10.116","volume":"15;22","author":"P Mathew","year":"2004","unstructured":"Mathew P, Thall P, Jones D, Perez C, Bucana C (2004) The platelet derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol 15;22:3323\u20133329","journal-title":"J Clin Oncol"},{"key":"1237_CR6","unstructured":"Celgene Corporation (2006) Investigator\u2019s brochure for LENALIDOMIDE capsules. Version 10, July 12, 2006"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1237-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-009-1237-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1237-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-1237-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T01:40:55Z","timestamp":1659058855000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-009-1237-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1,6]]},"references-count":6,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["1237"],"URL":"https:\/\/doi.org\/10.1007\/s00280-009-1237-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,6]]},"assertion":[{"value":"2 November 2009","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2009","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2010","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}